. home.aspx



GSK to invest $100M in Montana vaccine manufacturing site

April 24, 2019 / Kristin Jensen

The British drugmaker is acting in part to address a shingles vaccine shortage that has captured nationwide attention. Demand for GSK’s Shingrix zoster vaccine recombinant, approved in 2017, quickly outstripped supply and forced shipping delays and order limits last year. The Centers for Disease Control and Prevention is cautioning patients that the delays are likely to continue through this year. And AARP has offered advice to its members on how best to find the vaccine, including staying in close touch with the local pharmacy.
Even with the shortages, Shingrix became one of GSK’s most important growth drivers in its first full year, beating analysts’ early expectations. The vaccine chalked up sales of 784 million pounds, or about $1 billion, last year and ended 2018 with 98% market share, GSK reported in February. GSK is one of the few remaining large pharmaceutical makers in the vaccine market, along with Pfizer and Merck & Co. The company has more than ...